NVAX
Novavax
October 16, 2026 · intraday
- Rarity
- 1.81
- Peak move
- −13.22%
- Float cap
- $2.0B
Novavax is a Gaithersburg, Maryland-based vaccine company that develops recombinant protein-based nanoparticle vaccines and its proprietary Matrix-M adjuvant. It sells its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, to governments and health systems, and licenses its technology to partners such as Sanofi, Takeda and the Serum Institute of India, which uses Matrix-M in its malaria vaccine. Its pipeline spans seasonal influenza, COVID-influenza combinations, RSV and other infectious-disease candidates.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingBank of America raised its price target on Novavax to $8 from $7 while maintaining its Underperform/Sell rating.
- Key event
regulatory_approvalBelgium, Germany and Portugal approved Sanofi's Phase 3 trial of a combined COVID-influenza vaccine using Novavax's Nuvaxovid, with patient recruitment to begin in November 2026 and triggering a $125 million milestone payment from Sanofi to Novavax.
- Key event
government_contractTaiwan's CDC purchased 200,000 doses of Novavax XFG COVID-19 vaccine for its 2026-27 public vaccination program, with the first 150,000 doses arriving and cleared, and plans to buy an additional 174,000 doses for rollout to those aged 12+ from October 19.
- Key event
earnings_releaseNovavax issued a press release and investor presentation on October 15, 2026 reporting results of operations and financial condition, filed with the SEC as an 8-K signed by EVP and CFO C. Daniel Hobbs.
analyst_ratingCitigroup analyst Geoff Meacham maintained a Sell rating on Novavax and raised the price target to $8.00 from $7.00 on October 15, 2026, as part of a Q3 earnings preview for smid-cap biotechnology.
peer_disclosureThe NIH and the Foundation for the NIH are preparing a public-private partnership expected to begin in December 2026 to accelerate personalized cancer vaccine development, starting with pancreatic, liver and colorectal cancers and a subset of pediatric tumors.
regulatory_approvalThe FDA placed a clinical hold on Novavax's IND application for its COVID-19-influenza combination and stand-alone influenza vaccine candidates, citing a spontaneous report of serious motor neuropathy in a single CIC Phase 2 participant outside the U.S. who received the vaccine in January 2023.